Incidence, Risk Factors, and Outcomes in the Era of Modern Immunosuppression

Chukwuma Austin Chukwu,Anirudh Rao,Rachel Middleton,Philip A. Kalra
DOI: https://doi.org/10.3390/jcm13102734
IF: 3.9
2024-05-07
Journal of Clinical Medicine
Abstract:Introduction: Post-transplant cardiovascular disease (PTCVD) poses a significant challenge in kidney transplantation, potentially impacting graft outcomes and patient survival. This retrospective study aimed to investigate the incidence, risk factors, and consequential impact of PTCVD in kidney transplant recipients (KTRs) devoid of pre-existing cardiovascular disease (CVD). Method: The cohort comprised 1114 KTRs, with 749 individuals included after excluding those with pre-existing CVD and early graft loss. PTCVD encompasses ischemic heart disease, myocardial infarction, arrhythmias, heart failure, stroke, peripheral vascular disease, and valvular heart disease. Competing risk regression analysis was performed to identify predictors of PTCVD, while Cox proportional hazards analysis assessed the impact of PTCVD on graft and recipient survival. Results: The cumulative incidence of PTCVD at 5, 10, and 20 years was 5.4%, 14.3%, and 22.5%, respectively. Competing risk regression identified increased age (sub-hazard ratio [SHR], 1.22; p = 0.036) per decade, duration of dialysis (SHR, 1.07; p = 0.048) per year on dialysis, and the slope of the estimated glomerular filtration rate (SHR, 1.08; p = 0.008) mL/min/year decline as independent predictors of higher-risk PTCVD. A higher baseline estimated glomerular filtration rate (eGFR) was protective (SHR, 0.98; p = 0.032). PTCVD was not significantly associated with death-censored graft loss (adjusted hazard ratio [aHR] 1.31; p = 0.48) but was correlated with higher all-cause graft loss (aHR, 1.71; p = 0.011) and recipient mortality (aHR, 1.97; p = 0.004). Conclusion: This study provides insights into PTCVD predictors. Although not directly associated with graft loss, PTCVD significantly correlates with heightened mortality in kidney transplant recipients, emphasizing the need for enhanced clinical management and surveillance strategies.
medicine, general & internal
What problem does this paper attempt to address?
### Problems the paper attempts to solve This paper aims to explore the incidence, risk factors of cardiovascular disease (PTCVD) in kidney transplant recipients in the era of modern immunosuppressive therapy and its impact on graft and recipient survival. Specifically, the study focuses on kidney transplant recipients without pre - existing cardiovascular disease and evaluates the following aspects through retrospective analysis: 1. **Incidence of PTCVD**: The cumulative incidence of PTCVD at different time points (such as 5 years, 10 years, 20 years) after kidney transplantation was studied. 2. **Risk factors of PTCVD**: Independent predictors related to the occurrence of PTCVD were identified through competing - risk regression analysis. 3. **Impact of PTCVD on graft and recipient survival**: The Cox proportional - hazards model was used to evaluate the impact of PTCVD on death - censored graft loss (DCGL) and recipient death. ### Main findings - **Incidence of PTCVD**: - At 5 years, 10 years and 20 years, the cumulative incidences of PTCVD were 5.4%, 14.3% and 22.5% respectively. - The median time to CV event was 5.8 years, and the median CV - event - free survival time was 7.6 years. - **Risk factors of PTCVD**: - Competing - risk regression analysis showed that for every additional decade of recipient age (SHR: 1.22; 95% CI: 1.01 - 1.46; p = 0.036), for every additional year of dialysis time (SHR: 1.07; 95% CI: 1.00 - 1.14; p = 0.048) and the rate of decline in estimated glomerular filtration rate (eGFR) (SHR: 0.91; 95% CI: 0.86 - 0.98; p = 0.007) were independent predictors of PTCVD. - A higher baseline eGFR had a protective effect (SHR: 0.98; 95% CI: 0.96 - 1.00; p = 0.032). - **Impact of PTCVD on graft and recipient survival**: - PTCVD was not significantly associated with death - censored graft loss (adjusted hazard ratio [aHR] 1.31; p = 0.48), but was significantly associated with all - cause graft loss (aHR, 1.71; p = 0.011) and recipient death (aHR, 1.97; p = 0.004). ### Conclusion Although PTCVD does not directly lead to graft loss, it significantly increases the risk of death in kidney transplant recipients. Therefore, the study emphasizes the importance of strengthening clinical management and monitoring strategies to reduce the burden of PTCVD and thus improve the overall care of kidney transplant recipients.